GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:2000116111 | Esophagus | ESCC | regulation of cysteine-type endopeptidase activity | 158/8552 | 235/18723 | 1.67e-11 | 5.90e-10 | 158 |
GO:0043281111 | Esophagus | ESCC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 143/8552 | 209/18723 | 2.12e-11 | 7.31e-10 | 143 |
GO:0016049110 | Esophagus | ESCC | cell growth | 289/8552 | 482/18723 | 1.29e-10 | 3.77e-09 | 289 |
GO:0052547111 | Esophagus | ESCC | regulation of peptidase activity | 275/8552 | 461/18723 | 7.54e-10 | 1.88e-08 | 275 |
GO:000155819 | Esophagus | ESCC | regulation of cell growth | 248/8552 | 414/18723 | 2.97e-09 | 6.45e-08 | 248 |
GO:0070997111 | Esophagus | ESCC | neuron death | 216/8552 | 361/18723 | 3.49e-08 | 6.45e-07 | 216 |
GO:0052548111 | Esophagus | ESCC | regulation of endopeptidase activity | 253/8552 | 432/18723 | 3.68e-08 | 6.78e-07 | 253 |
GO:003253520 | Esophagus | ESCC | regulation of cellular component size | 227/8552 | 383/18723 | 4.77e-08 | 8.60e-07 | 227 |
GO:004677710 | Esophagus | ESCC | protein autophosphorylation | 138/8552 | 227/18723 | 2.98e-06 | 3.38e-05 | 138 |
GO:0051402110 | Esophagus | ESCC | neuron apoptotic process | 148/8552 | 246/18723 | 3.08e-06 | 3.47e-05 | 148 |
GO:1901214111 | Esophagus | ESCC | regulation of neuron death | 186/8552 | 319/18723 | 3.35e-06 | 3.73e-05 | 186 |
GO:003367420 | Esophagus | ESCC | positive regulation of kinase activity | 260/8552 | 467/18723 | 7.26e-06 | 7.22e-05 | 260 |
GO:00459267 | Esophagus | ESCC | negative regulation of growth | 148/8552 | 249/18723 | 7.88e-06 | 7.73e-05 | 148 |
GO:006056210 | Esophagus | ESCC | epithelial tube morphogenesis | 187/8552 | 325/18723 | 9.95e-06 | 9.44e-05 | 187 |
GO:1901216111 | Esophagus | ESCC | positive regulation of neuron death | 65/8552 | 97/18723 | 1.76e-05 | 1.56e-04 | 65 |
GO:005076710 | Esophagus | ESCC | regulation of neurogenesis | 203/8552 | 364/18723 | 6.10e-05 | 4.68e-04 | 203 |
GO:00083619 | Esophagus | ESCC | regulation of cell size | 107/8552 | 181/18723 | 1.81e-04 | 1.16e-03 | 107 |
GO:006156415 | Esophagus | ESCC | axon development | 251/8552 | 467/18723 | 2.41e-04 | 1.49e-03 | 251 |
GO:001097516 | Esophagus | ESCC | regulation of neuron projection development | 240/8552 | 445/18723 | 2.48e-04 | 1.53e-03 | 240 |
GO:0043525110 | Esophagus | ESCC | positive regulation of neuron apoptotic process | 40/8552 | 58/18723 | 2.83e-04 | 1.71e-03 | 40 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EPHA7 | insertion | Frame_Shift_Ins | novel | c.1353_1354insA | p.Glu452ArgfsTer26 | p.E452Rfs*26 | Q15375 | protein_coding | | | TCGA-D1-A102-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EPHA7 | insertion | In_Frame_Ins | novel | c.2401_2402insTTATCTGTGCGT | p.Arg801delinsIleIleCysAlaTrp | p.R801delinsIICAW | Q15375 | protein_coding | | | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EPHA7 | SNV | Missense_Mutation | novel | c.680N>C | p.Leu227Ser | p.L227S | Q15375 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-DD-AAVU-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
EPHA7 | SNV | Missense_Mutation | | c.473G>A | p.Gly158Asp | p.G158D | Q15375 | protein_coding | tolerated(0.42) | probably_damaging(1) | TCGA-G3-A7M9-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
EPHA7 | SNV | Missense_Mutation | novel | c.1910G>C | p.Arg637Pro | p.R637P | Q15375 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-ZS-A9CD-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
EPHA7 | SNV | Missense_Mutation | novel | c.152C>A | p.Pro51Gln | p.P51Q | Q15375 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-05-4396-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
EPHA7 | SNV | Missense_Mutation | | c.2668C>G | p.Leu890Val | p.L890V | Q15375 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-05-4410-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
EPHA7 | SNV | Missense_Mutation | | c.2086C>A | p.His696Asn | p.H696N | Q15375 | protein_coding | deleterious(0) | possibly_damaging(0.589) | TCGA-05-4410-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
EPHA7 | SNV | Missense_Mutation | rs773655407 | c.2384G>T | p.Gly795Val | p.G795V | Q15375 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-05-4424-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Targeted Molecular therapy | erlotinib | SD |
EPHA7 | SNV | Missense_Mutation | novel | c.1694G>T | p.Gly565Val | p.G565V | Q15375 | protein_coding | tolerated(0.17) | benign(0.052) | TCGA-05-4424-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Targeted Molecular therapy | erlotinib | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2045 | EPHA7 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, TYROSINE KINASE | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
2045 | EPHA7 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, TYROSINE KINASE | inhibitor | 381118815 | | |
2045 | EPHA7 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, TYROSINE KINASE | inhibitor | 249565821 | | |
2045 | EPHA7 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, TYROSINE KINASE | inhibitor | 249565850 | | |
2045 | EPHA7 | CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, TYROSINE KINASE | inhibitor | CHEMBL24828 | VANDETANIB | |